Breast Cancer Triple Marker Screening, IHC

Breast Cancer Triple Marker Screening, IHC

Breast Cancer Triple Marker Screening by Immunohistochemistry (IHC) is an advanced diagnostic test used to evaluate three important biomarkers in breast cancer tissue. This panel commonly includes ER (Estrogen Receptor), PR (Progesterone Receptor), and HER2/neu markers, which help determine the tumor’s behavior and guide personalized treatment planning.

Why is this test important?

• Helps classify the type of breast cancer
• Assists doctors in selecting targeted hormone or HER2 therapy
• Predicts treatment response and prognosis
• Supports accurate cancer management decisions

Sample Required

• Formalin-fixed paraffin-embedded (FFPE) tissue block or slides

Method

• Immunohistochemistry (IHC)

Recommended For

• Newly diagnosed breast cancer patients
• Tumor profiling before treatment planning
• Monitoring biomarker status in recurrent disease

Benefits

• Accurate biomarker assessment
• Supports precision oncology
• Faster treatment decision-making
• Reliable and clinically significant results

#BreastCancer #IHCTest #CancerScreening #HER2 #ERPR #OncologyDiagnostics #PrecisionMedicine #BiocareLaboratories #Dermafact #gynofact